Webinar Preso Today at NWR conference, page-13

Some great hints on that presentation.

Access Bio's share price has tripled on the back of FDA approval and Atomos test will be using the same strip.

Their agreement is for 2 million units plus another 2 million units possible extension and Atomo can start selling with Access Bio in other markets in South America without FDA approval.

If I heard correctly the company expects capacity to be around 12-13 million units a year for Galileo and another 6 million for Pascal. Could be some new HIV deals around the corner.